Salinomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Salinomycin
Accession Number
DB11544
Description
Not Available
Type
Small Molecule
Groups
Vet approved
Structure
Thumb
Weight
Average: 751.011
Monoisotopic: 750.491813074
Chemical Formula
C42H70O11
Synonyms
  • Procoxacin

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Salinomycin is combined with Acenocoumarol.
DicoumarolThe risk or severity of bleeding can be increased when Salinomycin is combined with Dicoumarol.
FluindioneThe risk or severity of bleeding can be increased when Salinomycin is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Salinomycin.
PhenindioneThe risk or severity of bleeding can be increased when Salinomycin is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Salinomycin is combined with Phenprocoumon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Salinomycin.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Salinomycin.
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Salinomycin.
WarfarinThe risk or severity of bleeding can be increased when Salinomycin is combined with Warfarin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Salinomycin sodium92UOD3BMEK55721-31-8YPZYGIQXBGHDBH-UZHRAPRISA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Diterpene glycosides
Alternative Parents
Diterpenoids / Fatty alcohols / Branched fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Ketals / Beta-hydroxy ketones / Oxanes / Pyrans / Tertiary alcohols
show 8 more
Substituents
Acetal / Alcohol / Aliphatic heteropolycyclic compound / Beta-hydroxy ketone / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether / Diterpene glycoside
show 20 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
diterpene glycoside (CHEBI:80025)

Chemical Identifiers

UNII
62UXS86T64
CAS number
53003-10-4
InChI Key
KQXDHUJYNAXLNZ-XQSDOZFQSA-N
InChI
InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1
IUPAC Name
(2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5⁷.3⁵]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid
SMILES

References

General References
  1. Potter LM, Blake JP, Blair ME, Bliss BA, Denbow DM: Salinomycin toxicity in turkeys. Poult Sci. 1986 Oct;65(10):1955-9. [PubMed:3797377]
  2. Horrox NE: Salinomycin poisoning in turkeys. Vet Rec. 1984 Jan 14;114(2):52. [PubMed:6719809]
  3. Aleman M, Magdesian KG, Peterson TS, Galey FD: Salinomycin toxicosis in horses. J Am Vet Med Assoc. 2007 Jun 15;230(12):1822-6. [PubMed:17571983]
  4. Rollinson J, Taylor FG, Chesney J: Salinomycin poisoning in horses. Vet Rec. 1987 Aug 8;121(6):126-8. [PubMed:3672848]
  5. Pott JM: Salinomycin toxicity in pigs. Vet Rec. 1990 Dec 1;127(22):554. [PubMed:2281597]
  6. Vertesy L, Heil K, Fehlhaber HW, Ziegler W: Microbial decomposition of salinomycin. J Antibiot (Tokyo). 1987 Mar;40(3):388-90. [PubMed:3570991]
  7. Stuart JC: Salinomycin poisoning in turkeys. Vet Rec. 1983 Dec 17;113(25):597. [PubMed:6665966]
  8. Kavanagh NT, Sparrow DS: Salinomycin toxicity in pigs. Vet Rec. 1990 Nov 17;127(20):507. [PubMed:2275094]
  9. Harries N: Alberta. Salinomycin toxicity in turkeys. Can Vet J. 1991 Feb;32(2):117. [PubMed:17423737]
  10. Huyben MW, Sol J, Counotte GH, Roumen MP, Borst GH: Salinomycin poisoning in veal calves. Vet Rec. 2001 Aug 11;149(6):183-4. [PubMed:11530905]
KEGG Drug
D08502
KEGG Compound
C15690
ChemSpider
2342058
RxNav
1311566
ChEBI
80025
ChEMBL
CHEMBL1208572
ZINC
ZINC000085540254
Wikipedia
Salinomycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00297 mg/mLALOGPS
logP4.48ALOGPS
logP7.51ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.45ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area161.21 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity200.07 m3·mol-1ChemAxon
Polarizability81.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U: The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010 Jun 15;45(1):86-92. doi: 10.1016/j.bcmd.2010.03.008. Epub 2010 May 4. [PubMed:20444629]
  2. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 2012 Aug;30(4):1311-8. doi: 10.1007/s10637-011-9685-6. Epub 2011 May 15. [PubMed:21573958]

Drug created on February 26, 2016 10:41 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates